Figure 1. **Comparison of Monomeric TGF-Beta 3 With Dimeric TGF-Beta 3 by SDS-PAGE (Coomassie Blue stained)**

Track	Sample	Concentration loaded per track
1	Monomeric TGF-Beta 3	3µg
2	Dimeric TGF-Beta 3	3µg
3	Invitrogen Mark 12 molecular weight standards	10µg

Non-Reduced Conditions **Reduced Conditions**




Figure 2. Template for Rat Incisional Wounding





Figure 3 **Wound Site Treatment.**

Group	Treatment/sample	Concentration (ng/100μL)
A	Monomeric 'Wild-type' TGF-Beta 3	50
B	Monomeric 'Wild-type' TGF-Beta 3	100
G	TGF-Beta 3 'Wild-type' Dimer	50
H	0.25 M Maltose (Placebo control)	N/A
I	Naïve (no treatment control)	N/A

Figure 4. Day 3 Mean (± SD) Macroscore for Incisional wounds (A and B) Treated with Monomeric and Dimeric 'Wild-type' TGF-Beta 3.




** Significantly increased healing compared to naïve wounds ($p<0.01$)

Figure 5. **Wound site treatment.**

Group	Treatment/sample	Concentration (ng/100μL)
A	Monomeric 'Wild-type' TGF-Beta 3	50
B	Monomeric 'Wild-type' TGF-Beta 3	100
K	TGF-Beta 3 'Wild-type' Dimer	50
L	0.25 M Maltose (Placebo control)	N/A
M	Naïve (no treatment control)	N/A


Figure 6. Day 70 Mean (± SD) Macroscore for Incisional Wounds (A and B) Treated with Monomeric and Dimeric 'Wild-type'TGF-Beta 3.




** Significantly decreased scarring compared to placebo treated wounds ($p<0.01$)

Figure 7. Representative Macroscopic Scar Images (70 days Post-Wounding).


TGF-Beta 3 'Wild-type' Monomer (50ng/100μL)



TGF-Beta 3 'Wild-type' Monomer (100ng/100μL)



TGF-Beta 3 'Wild-type' Dimer (50ng/100μL)



Placebo (0.25M Maltose)




Figure 7 Cont'd. Representative Macroscopic Scar Images (70 days Post-Wounding).

Naïve





Figure 8. Representative Microscopic Scar Images of Wounds treated with Monomeric and Dimeric 'Wild-type' TGF-Beta 3 (70 days Post-Wounding).




TGF-Beta 3 'Wild-type' Dimer (50ng/100µl)

Key


E = Epidermis
ND = Normal Dermis
S = Scar

Figure 8 Cont'd. Representative Microscopic Scar Images of Wounds treated with Monomeric and Dimeric 'Wild-type' TGF-Beta 3 (70 days Post-Wounding) .



Naïve Control


Placebo (0.25M Maltose)



TGF-Beta 3 'Wild-type' Monomer (50ng/100µL)

TGF-Beta 3 'Wild-type' Monomer (100ng/100µL)

FIG. 9



Lane	Sample
1	Mark 12 Standard
2	Clone1 3hr Post-Induction (3μL)
3	Clone 2 3hr Post-Induction (3μL)
4	Clone 3 3hr Post-Induction (3μL)
5	Clone 4 3hr Post-Induction (3μL)
6	Mark 12 standard

FIG. 10




Samples from Experiment Numbers
Non-reduced TGF-Beta 3 standard
Dimeric TGF-Beta 3
Monomeric TGF-Beta 3

FIG. 11


PD205071205 01 Butyl:10 UV1 280nm
PD205071205 01 Butyl:10 UV2 254nm
PD205071205 01 Butyl:10 Cond
PD205071205 01 Butyl:10 Logbook
mAU
5000
4000
3000
2000
1000
0
TGF-Beta 3
Monomer and
Dimer
Equilibration
Begin load
Begin Wash
Elution
Water flush
0
1000
2000
3000
4000
5000
ml